Patterns of normal brain activity may predispose individuals to different symptoms of psychosis

June 17, 2008

Washington, DC - A new study released today offers a potential predictive technique to anticipate how individuals might behave during a psychotic episode. The study, in the June 18 issue of The Journal of Neuroscience, related the brain activity of healthy participants to how they behaved after exposure to ketamine (a psychosis-inducing drug that mimics schizophrenia symptoms). The findings help explain why schizophrenia symptoms vary greatly from person to person and may ultimately help personalize diagnosis and intervention.

"In schizophrenia, why might one individual suffer predominantly from biz arre and unpleasant perceptions, while another is haunted by frightening beliefs that he is being persecuted, and yet another is mainly troubled by difficulties in ordering his thoughts and motivating himself?" asked Paul Fletcher, MD, at the University of Cambridge, the senior researcher who led the study.

Fletcher and colleagues hypothesize that these different symptoms have distinct biological underpinnings, each of which may disrupt normal cognitive processes. The researchers reason that individual differences in normal cognitive functioning -- that is, each person's unique patterns of brain activity -- might indicate which processes are most at risk of being compromised by drug-induced psychosis or schizophrenia.

Schizophrenia symptoms include "negative" ones that involve the loss of normal behaviors, including social withdrawal and reductions in speech, and "positive" ones that involve the gain of abnormal ones (or the excess of normal behaviors) such as hallucinations, delusions, and disordered thought. However, schizophrenia symptoms vary unpredictably from person to person.

Ketamine, known by the street name "Special K," is an often-abused analgesic that induces both positive and negative symptoms. Like schizophrenia, the effects of ketamine are variable and unpredictable. Ketamine works by blocking receptors for the neurotransmitter glutamate, which are also implicated in schizophrenia.

Using functional magnetic resonance imaging (fMRI), the researchers profiled 15 people exposed to either ketamine or placebo while they did a variety of cognitive tasks. The researchers then evaluated participants' behaviors using several accepted psychiatric scales. One month later, participants returned to repeat the testing in the opposite drug condition, so each participant was imaged and observed after exposure to both placebo and ketamine.

The researchers found that increased brain activity during some tasks in the placebo condition predicted behaviors in the ketamine condition. The brain's temporal lobe is important in speech, hearing, and memory, and the frontal lobe in "executive" functions -- planning, decision-making, and correcting and troubleshooting errors. Participants who showed more frontal and temporal brain activity while imagining the sounds of voices in the placebo condition were more likely to experience strange perceptions in the ketamine condition. Others who showed increased activity in these brain regions while trying to complete simple sentences were more likely to have disordered thoughts when exposed to ketamine.

In contrast to these positive symptoms, participants who showed increased frontal response to an attentional task in the placebo condition showed increased vulnerability to negative symptoms in the ketamine condition. Similarly, participants who showed increased response in frontal, thalamic, and caudate regions -- brain areas linked together in a circuit that is important in executive and motor functions, and which is impaired in many neuropsychiatric diseases -- also tended to show negative symptoms in the ketamine condition.

"These researchers have certainly taken a great step forward for our understanding of schizophrenia," said Graham Williams, DPhil, at Yale University, an expert unaffiliated with the study. "At last, we have a tangible, biological approach to unraveling the complex and mystifying symptoms displayed by patients with schizophrenia," Williams said.

The study authors note that the brain profiles associated with ketamine-induced symptoms do not imply increased disease risk in the healthy volunteers, but offer insight into how disease and drug use can cause different effects in different people.

"Our findings may provide a vulnerability marker to predict psychotic symptoms induced by drugs or disease," said study author Fletcher. "This perhaps raises the prospect of early intervention strategies targeted toward schizophrenia patients' individual patterns of symptom vulnerability," he said.
-end-
The research was supported by the Medical Research Council, The Wellcome Trust, and the Bernard Wolfe Health Neuroscience Fund.

The Journal of Neuroscience is published by the Society for Neuroscience, an organization of more than 38,000 basic scientists and clinicians who study the brain and nervous system. Fletcher can be reached at pcf22@cam.ac.uk.

Society for Neuroscience

Related Schizophrenia Articles from Brightsurf:

Schizophrenia: When the thalamus misleads the ear
Scientists at the University of Geneva (UNIGE) and the Synapsy National Centre of Competence in Research (NCCR) have succeeded in linking the onset of auditory hallucinations - one of the most common symptoms of schizophrenia - with the abnormal development of certain substructures of a region deep in the brain called the thalamus.

Unlocking schizophrenia
New research, led by Prof. LIU Bing and Prof. JIANG Tianzi from the Institute of Automation of the Chinese Academy of Sciences and their collaborators have recently developed a novel imaging marker that may help in the personalized medicine of psychiatric disorders.

Researchers discover second type of schizophrenia
In a study of more than 300 patients from three continents, over one third had brains that looked similar to healthy people.

New clues into the genetic origins of schizophrenia
The first genetic analysis of schizophrenia in an ancestral African population, the South African Xhosa, appears in the Jan.

Dietary supplement may help with schizophrenia
A dietary supplement, sarcosine, may help with schizophrenia as part of a holistic approach complementing antipsychotic medication, according to a UCL researcher.

Schizophrenia: Adolescence is the game-changer
Schizophrenia may be related to the deletion syndrome. However, not everyone who has the syndrome necessarily develops psychotic symptoms.

Study suggests overdiagnosis of schizophrenia
In a small study of patients referred to the Johns Hopkins Early Psychosis Intervention Clinic (EPIC), Johns Hopkins Medicine researchers report that about half the people referred to the clinic with a schizophrenia diagnosis didn't actually have schizophrenia.

The ways of wisdom in schizophrenia
Researchers at UC San Diego School of Medicine report that persons with schizophrenia scored lower on a wisdom assessment than non-psychiatric comparison participants, but that there was considerable variability in levels of wisdom, and those with higher scores displayed fewer psychotic symptoms.

Recognizing the uniqueness of different individuals with schizophrenia
Individuals diagnosed with schizophrenia differ greatly from one another. Researchers from Radboud university medical center, along with colleagues from England and Norway, have demonstrated that very few identical brain differences are shared amongst different patients.

Resynchronizing neurons to erase schizophrenia
Today, a decisive step in understanding schizophrenia has been taken.

Read More: Schizophrenia News and Schizophrenia Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.